Use este identificador para citar ou linkar para este item: http://repositorio.ufc.br/handle/riufc/10271
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorViana, Glauce S. Barros-
dc.contributor.authorPessoa, Igor X.-
dc.contributor.authorFerreira, Pollyana L. Tavares-
dc.contributor.authorCarvalho, Antônio Germano G.-
dc.contributor.authorGarcia, Francisca Adilfa O.-
dc.contributor.authorMenezes, Silvana M. Siqueira-
dc.contributor.authorNeves, Kelly Rose Tavares-
dc.contributor.authorAlves, Ana Paula Negreiros Nunes-
dc.contributor.authorCerqueira, Gilberto Santos-
dc.contributor.authorBrito, Gerly Anne C.-
dc.date.accessioned2014-12-15T13:30:40Z-
dc.date.available2014-12-15T13:30:40Z-
dc.date.issued2014-05-
dc.identifier.citationVIANA, G. S. B. et al. Minocycline decreases blood glucose and triglyceride levels and reverses histological and immunohisto-chemical alterations in pancreas, liver and kidney of alloxan-induced diabetic rats. Journal of Diabetes and Endocrinology, v. 5, n. 4, p. 2-40, maio, 2014.pt_BR
dc.identifier.issn2141-2685-
dc.identifier.urihttp://www.repositorio.ufc.br/handle/riufc/10271-
dc.description.abstractIncreasing evidence suggests that oxidative stress and inflammation play major roles in diabetes mellitus and its complications. Furthermore, hyperg lycemia increases the produc tion of free radicals, resulting in oxidative stress. Minocycline presents potent anti-inflammatory and antioxidant activities, as evaluated by in vivo and in vitro models. In the present study, the minocycline anti-diabetic effect was assessed in the model of alloxan-induced diabetes. Alloxan was injected to male Wistar rats (50 mg/kg, intravenously), and their blood was collected 48 h later and also after treatments, for measurements of glycemia, triglycerides, cholesterol and liver transaminases. Groups of untreated diabetic controls and diabetic treated with minoc ycline (1 to 50 mg/kg, peritoneally, p.o.) or glibenclamide (5 mg/kg, p.o., as reference), for different periods, were used. Furthermore, slices of pancreas, liver and kidney were submitted to hi stological and immunohistochemical analyses. While significant decreases in glucose and triglycerides were shown at the 5th and mainly at the 30th days after minocycline treatments, as compared to the untreated diabetic group, no changes were observed in total cholesterol, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels. Histological analyses of pancreas, liver and kidney showed that minocycline significantly reversed tissue alterations, as those seen in untreated diab etic animals. Besides, minocycline also reduced tumor necrosis factor (TNF)-alpha, cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS) expressions. The beneficial minocycline effects in diabet es could be due, at least partly, to its anti- inflammatory and antioxidant properties, indicating that this drug may be a therapeutic alternative in diabetes mellitus and other pathological condition s where inflammation plays a significant role.pt_BR
dc.language.isoenpt_BR
dc.publisherJournal of Diabetes and Endocrinologypt_BR
dc.subjectMinociclinapt_BR
dc.subjectDiabetes Mellituspt_BR
dc.subjectHiperglicemiapt_BR
dc.subjectHipertrigliceridemiapt_BR
dc.titleMinocycline decreases blood glucose and triglyceride levels and reverses histol ogical and immunohisto- chemical alterations in pancreas, liver and kidney of alloxan-induced diabetic ratspt_BR
dc.typeArtigo de Periódicopt_BR
Aparece nas coleções:DFIFA - Artigos publicados em revista científica

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
2014_art_gscerqueira.pdf2,41 MBAdobe PDFVisualizar/Abrir


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.